BidaskClub Upgrades Aurinia Pharmaceuticals (AUPH) to Buy

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Several other research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. ValuEngine raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 16th. Cantor Fitzgerald set a $18.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, September 26th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Aurinia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $11.95.

Shares of Aurinia Pharmaceuticals stock opened at $6.28 on Wednesday. Aurinia Pharmaceuticals has a 1 year low of $4.41 and a 1 year high of $6.69. The firm has a market cap of $524.86 million, a P/E ratio of -6.83 and a beta of 2.23.



Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). Aurinia Pharmaceuticals had a negative return on equity of 36.10% and a negative net margin of 7,280.85%. The business had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.07 million. As a group, analysts forecast that Aurinia Pharmaceuticals will post -0.73 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its holdings in Aurinia Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after buying an additional 95,650 shares in the last quarter. Franklin Resources Inc. increased its holdings in Aurinia Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after buying an additional 105,300 shares in the last quarter. Ironwood Investment Management LLC increased its holdings in Aurinia Pharmaceuticals by 18.0% in the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after buying an additional 33,279 shares in the last quarter. Stanley Laman Group Ltd. purchased a new position in Aurinia Pharmaceuticals in the second quarter valued at $276,000. Finally, Jane Street Group LLC purchased a new position in Aurinia Pharmaceuticals in the third quarter valued at $182,000. 25.18% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: Should you buy a closed-end mutual fund?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply